TrialThe New England journal of medicine2016

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.

Hagop M Kantarjian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.